Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 51
Filtrer
1.
Obes Res Clin Pract ; 14(4): 339-344, 2020.
Article de Anglais | MEDLINE | ID: mdl-32561167

RÉSUMÉ

BACKGROUND: Traditionally, obesity has been regarded as protective against osteoporosis. However, recent accumulating evidences suggest that visceral obesity can increase the risk of osteoporosis and obesity-driven dysfunctional metabolic activity in visceral adipose tissue (VAT) is considered as a key underlying mechanism. Visceral obesity is known to increase during menopausal transition.18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is an established method to assess the degree of VAT metabolic activity. We aimed to investigate the association between VAT metabolic activity evaluated by 18F-FDG PET/CT and osteoporosis in healthy postmenopausal Korean women. METHODS: A total of 115 postmenopausal women who underwent routine health check-up were enrolled in this study, retrospectively. They all underwent dual-energy X-ray absorptiometry and 18F-FDG PET/CT. Osteoporosis was defined as bone mineral density (BMD) T-score ≤ -2.5 at either lumbar spine or femoral neck. VAT metabolic activity was defined as the maximum standardized uptake value (SUVmax) of VAT divided by the SUVmax of subcutaneous adipose tissue (V/S ratio). RESULTS: The participants with osteoporosis showed significantly higher V/S ratio, age, body mass index, waist circumference, and postmenopausal period than the participants without osteoporosis. V/S ratio of 1.33 was proposed as an optimal cut-off value for identifying osteoporosis. Furthermore, V/S ratio was the most significant predictive factor for osteoporosis in postmenopausal woman by uni-and multivariate analyses. Interestingly, V/S ratio showed significant positive correlation with high sensitivity C-reactive protein, a surrogate marker for systemic inflammation. CONCLUSION: VAT metabolic activity assessed by 18F-FDG PET/CT is associated with osteoporosis in healthy postmenopausal Korean women.


Sujet(s)
Fluorodésoxyglucose F18 , Graisse intra-abdominale , Ostéoporose post-ménopausique , Femelle , Humains , Graisse intra-abdominale/imagerie diagnostique , Graisse intra-abdominale/métabolisme , Ostéoporose post-ménopausique/imagerie diagnostique , Tomographie par émission de positons couplée à la tomodensitométrie , Post-ménopause , Radiopharmaceutiques , République de Corée , Études rétrospectives
2.
Int J Mol Sci ; 20(2)2019 Jan 17.
Article de Anglais | MEDLINE | ID: mdl-30658428

RÉSUMÉ

Bone metastasis is the terminal stage disease of prostate, breast, renal, and lung cancers, and currently no therapeutic approach effectively cures or prevents its progression to bone metastasis. One of the hurdles to the development of new drugs for bone metastasis is the complexity and heterogeneity of the cellular components in the metastatic bone microenvironment. For example, bone cells, including osteoblasts, osteoclasts, and osteocytes, and the bone marrow cells of diverse hematopoietic lineages interact with each other via numerous cytokines and receptors. c-Met tyrosine kinase receptor and its sole ligand hepatocyte growth factor (HGF) are enriched in the bone microenvironment, and their expression correlates with the progression of bone metastasis. However, no drugs or antibodies targeting the c-Met/HGF signaling axis are currently available in bone metastatic patients. This significant discrepancy should be overcome by further investigation of the roles and regulation of c-Met and HGF in the metastatic bone microenvironment. This review paper summarizes the key findings of c-Met and HGF in the development of novel therapeutic approaches for bone metastasis.


Sujet(s)
Antinéoplasiques/usage thérapeutique , Tumeurs osseuses/traitement médicamenteux , Tumeurs osseuses/métabolisme , Facteur de croissance des hépatocytes/métabolisme , Protéines proto-oncogènes c-met/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Animaux , Antinéoplasiques/pharmacologie , Tumeurs osseuses/anatomopathologie , Tumeurs osseuses/secondaire , Évolution de la maladie , Humains , Thérapie moléculaire ciblée , Ostéoblastes/effets des médicaments et des substances chimiques , Ostéoblastes/métabolisme , Ostéoclastes/effets des médicaments et des substances chimiques , Ostéoclastes/métabolisme , Microenvironnement tumoral/effets des médicaments et des substances chimiques
3.
Brachytherapy ; 16(1): 116-125, 2017.
Article de Anglais | MEDLINE | ID: mdl-27876378

RÉSUMÉ

PURPOSE: To analyze the toxicities and dose-volume histogram parameters of external-beam and magnetic resonance imaging-based intracavitary brachytherapy in cervical cancer patients. METHODS AND MATERIALS: Acute and late toxicities were assessed in 135 patients divided into four groups: group 1, grade 0; group 2, grades 1-4; group 3, grades 0-1; and group 4, grades 2-4. The doses at the International Commission on Radiation Units and Measurements (DICRU) and minimum doses to the most exposed 0.1, 1, 2, and 5 cc (D0.1cc, D1cc, D2cc, and D5cc) of normal organs were calculated as equivalent doses in 2 Gy (α/ß = 3). RESULTS: The median follow-up was 35.2 months. For rectum, DICRU, D0.1cc, D1cc, and D2cc were significantly different between groups 1 and 2 and DICRU, D0.1cc, and D1cc between groups 3 and 4. For bladder, D0.1cc, D1cc, and D2cc were significantly different between groups 1 and 2 and DICRU, D1cc, D2cc, and D5cc between groups 3 and 4. Grade 2-4 bladder toxicity occurred in fewer patients with D2cc ≤ 95 Gy than those with D2cc > 95 Gy (7% vs. 22%, p = 0.014). CONCLUSIONS: DICRU, D0.1cc, D1cc, and D2cc are relevant for predicting late rectal toxicities. The patients with bladder D2cc > 95 Gy are required to be in close observation for severe late toxicities.


Sujet(s)
Adénocarcinome/radiothérapie , Curiethérapie/méthodes , Carcinome adénosquameux/radiothérapie , Carcinome épidermoïde/radiothérapie , Lésions radiques/épidémiologie , Dosimétrie en radiothérapie , Tumeurs du col de l'utérus/radiothérapie , Adénocarcinome/imagerie diagnostique , Adénocarcinome/anatomopathologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Curiethérapie/effets indésirables , Carcinome adénosquameux/imagerie diagnostique , Carcinome adénosquameux/anatomopathologie , Carcinome épidermoïde/imagerie diagnostique , Carcinome épidermoïde/anatomopathologie , Cystite/épidémiologie , Cystite/étiologie , Diarrhée/épidémiologie , Diarrhée/étiologie , Femelle , Humains , Maladies intestinales/épidémiologie , Maladies intestinales/étiologie , Intestin grêle/imagerie diagnostique , Imagerie par résonance magnétique , Adulte d'âge moyen , Organes à risque/imagerie diagnostique , Lésions radiques/étiologie , Planification de radiothérapie assistée par ordinateur , Rectum/imagerie diagnostique , Vessie urinaire/imagerie diagnostique , Tumeurs du col de l'utérus/imagerie diagnostique , Tumeurs du col de l'utérus/anatomopathologie
4.
Strahlenther Onkol ; 192(12): 922-930, 2016 Dec.
Article de Anglais | MEDLINE | ID: mdl-27734106

RÉSUMÉ

OBJECTIVE: The purpose of this work was to identify prognostic factors for survival after magnetic resonance image (MRI)-guided brachytherapy combined with external beam radiotherapy for cervical cancer. MATERIAL AND METHODS: External beam radiotherapy of 45-50.4 Gy was delivered by either three-dimensional conformal radiotherapy or helical tomotherapy. Patients also received high-dose-rate MRI-guided brachytherapy of 5 Gy in 6 fractions. RESULTS: We analyzed 128 patients with International Federation of Gynecology and Obstetrics stage IB-IVB cervical cancer who underwent MRI-guided brachytherapy. Most patients (96 %) received concurrent chemotherapy. Pelvic lymph node metastases and para-aortic lymphadenopathies were found in 62 % and 14 % of patients, respectively. The median follow-up time was 44 months. Complete remission was achieved in 119 of 128 patients (93 %). The 5­year local recurrence-free, cancer-specific, and overall survival rates were 94, 89, and 85 %, respectively. Negative pelvic lymphadenopathy, gross tumor volume (GTV) dose covering 90 % of the target (GTV D90) of >110 Gy, and treatment duration ≤56 days were associated with better overall survival in univariate analyses. Multivariable analysis showed that GTV D90 of >110 Gy and treatment duration ≤56 days were possibly associated with overall survival with near-significant P-values of 0.062 and 0.073, respectively. CONCLUSIONS: The outcome of MRI-guided brachytherapy combined with external beam radiotherapy in patients with cervical cancer was excellent. GTV D90 of >110 Gy and treatment duration ≤56 days were potentially associated with overall survival.


Sujet(s)
Curiethérapie/mortalité , Imagerie par résonance magnétique/statistiques et données numériques , Lésions radiques/mortalité , Radiothérapie guidée par l'image/mortalité , Tumeurs du col de l'utérus/mortalité , Tumeurs du col de l'utérus/radiothérapie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Curiethérapie/statistiques et données numériques , Association thérapeutique/mortalité , Femelle , Humains , Adulte d'âge moyen , Prévalence , Lésions radiques/prévention et contrôle , Dosimétrie en radiothérapie , Radiothérapie guidée par l'image/méthodes , Radiothérapie guidée par l'image/statistiques et données numériques , Radiothérapie conformationnelle avec modulation d'intensité/mortalité , Radiothérapie conformationnelle avec modulation d'intensité/statistiques et données numériques , Maladies du rectum/mortalité , Maladies du rectum/prévention et contrôle , Facteurs de risque , Taux de survie , Résultat thérapeutique , Tumeurs du col de l'utérus/anatomopathologie
5.
Radiother Oncol ; 117(3): 501-4, 2015 Dec.
Article de Anglais | MEDLINE | ID: mdl-26293200

RÉSUMÉ

This study describes the development and evaluation of a new dosimetric system for proton therapy using an array of fiber-optic Cerenkov radiation sensors (AFCRS). The AFCRS was superior to a conventional, multi-layer ion chamber (MLIC) system in real-time data acquisition and cost effectiveness.


Sujet(s)
Protonthérapie/instrumentation , Radiométrie/instrumentation , Technologie des fibres optiques , Humains
6.
J Adv Prosthodont ; 7(2): 138-45, 2015 Apr.
Article de Anglais | MEDLINE | ID: mdl-25932312

RÉSUMÉ

PURPOSE: The objective of this study was to conduct an in vitro comparative evaluation of polished and laserdimpled titanium (Ti) surfaces to determine whether either surface has an advantage in promoting the attachment of epithelial-like cells and fibroblast to Ti. MATERIALS AND METHODS: Forty-eight coin-shaped samples of commercially pure, grade 4 Ti plates were used in this study. These discs were cleaned to a surface roughness (Ra: roughness centerline average) of 180 nm by polishing and were divided into three groups: SM (n=16) had no dimples and served as the control, SM15 (n=16) had 5-µm dimples at 10-µm intervals, and SM30 (n=16) had 5-µm dimples at 25-µm intervals in a 2 × 4 mm(2) area at the center of the disc. Human gingival squamous cell carcinoma cells (YD-38) and human lung fibroblasts (MRC-5) were cultured and used in cell proliferation assays, adhesion assays, immunofluorescent staining of adhesion proteins, and morphological analysis by SEM. The data were analyzed statistically to determine the significance of differences. RESULTS: The adhesion strength of epithelial cells was higher on Ti surfaces with 5-µm laser dimples than on polished Ti surfaces, while the adhesion of fibroblasts was not significantly changed by laser treatment of implant surfaces. However, epithelial cells and fibroblasts around the laser dimples appeared larger and showed increased expression of adhesion proteins. CONCLUSION: These findings demonstrate that laser dimpling may contribute to improving the periimplant soft tissue barrier. This study provided helpful information for developing the transmucosal surface of the abutment.

7.
Article de Anglais | MEDLINE | ID: mdl-24462964

RÉSUMÉ

The industrial application of nanotechnology, particularly using zinc oxide (ZnO), has grown rapidly, including products such as cosmetics, food, rubber, paints, and plastics. However, despite increasing population exposure to ZnO, its potential genotoxicity remains controversial. The biological effects of nanoparticles depend on their physicochemical properties. Preparations with well-defined physico-chemical properties and standardized test methods are required for assessing the genotoxicity of nanoparticles. In this study, we have evaluated the genotoxicity of four kinds of ZnO nanoparticles: 20nm and 70nm size, positively or negatively charged. Four different genotoxicity tests (bacterial mutagenicity assay, in vitro chromosomal aberration test, in vivo comet assay, and in vivo micronucleus test, were conducted, following Organization for Economic Cooperation and Development (OECD) test guidelines with good laboratory practice (GLP) procedures. No statistically significant differences from the solvent controls were observed. These results suggest that surface-modified ZnO nanoparticles do not induce genotoxicity in in vitro or in vivo test systems.


Sujet(s)
Altération de l'ADN , Nanoparticules métalliques/toxicité , Oxyde de zinc/toxicité , Animaux , Cellules cultivées , Test des comètes/méthodes , Cricetinae , Cricetulus , Mâle , Souris , Souris de lignée ICR , Tests de micronucleus , Rats , Rat Sprague-Dawley
9.
Int J Nanomedicine ; 9 Suppl 2: 3-10, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565821

RÉSUMÉ

Currently, products made with nanomaterials are used widely, especially in biology, bio-technologies, and medical areas. However, limited investigations on potential toxicities of nanomaterials are available. Hence, diverse and systemic toxicological data with new methods for nanomaterials are needed. In order to investigate the nanotoxicology of nanoparticles (NPs), the Research Team for Nano-Associated Safety Assessment (RT-NASA) was organized in three parts and launched. Each part focused on different contents of research directions: investigators in part I were responsible for the efficient management and international cooperation on nano-safety studies; investigators in part II performed the toxicity evaluations on target organs such as assessment of genotoxicity, immunotoxicity, or skin penetration; and investigators in part III evaluated the toxicokinetics of NPs with newly developed techniques for toxicokinetic analyses and methods for estimating nanotoxicity. The RT-NASA study was carried out in six steps: need assessment, physicochemical property, toxicity evaluation, toxicokinetics, peer review, and risk communication. During the need assessment step, consumer responses were analyzed based on sex, age, education level, and household income. Different sizes of zinc oxide and silica NPs were purchased and coated with citrate, L-serine, and L-arginine in order to modify surface charges (eight different NPs), and each of the NPs were characterized by various techniques, for example, zeta potentials, scanning electron microscopy, and transmission electron microscopy. Evaluation of the "no observed adverse effect level" and systemic toxicities of all NPs were performed by thorough evaluation steps and the toxicokinetics step, which included in vivo studies with zinc oxide and silica NPs. A peer review committee was organized to evaluate and verify the reliability of toxicity tests, and the risk communication step was also needed to convey the current findings to academia, industry, and consumers. Several limitations were encountered in the RT-NASA project, and they are discussed for consideration for improvements in future studies.


Sujet(s)
Nanoparticules/toxicité , Nanotechnologie , Silice/toxicité , Oxyde de zinc/toxicité , Humains , Nanotechnologie/organisation et administration , Nanotechnologie/normes , Évaluation des besoins , Sécurité
10.
Int J Nanomedicine ; 9 Suppl 2: 11-20, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565822

RÉSUMÉ

BACKGROUND: The purpose of our study was to understand consumers' risk awareness and need for relevant information about nanotechnology and nanoparticles contained in products currently being sold in Korea. METHODS: One thousand and seven adult consumers (aged 20-50 years) were randomly selected from all over South Korea between November 1 and 9, 2010. We surveyed the origin and degree of their concern and their need for information and education regarding nanomaterials. RESULTS: Analysis of the survey results showed no significant differences in responses by sex, age, and level of education, but significant differences were found in responses based on average monthly household income. Our research showed that consumers have vague expectations for and positive image of nanotechnology and nanoproducts but do not clearly understand what they are. In addition, we found that preparing and disseminating information to consumers is required in order to provide correct information about nanotechnology to the public. CONCLUSION: A communication system should be established among the multiple stakeholders involved with nanomaterials to address consumer expectations and concerns. Further, a safety evaluation system must be set up, the results of which should be processed by a reliable expert group so they can be disseminated to the public.


Sujet(s)
Comportement du consommateur , Connaissances, attitudes et pratiques en santé , Nanostructures , Nanotechnologie , Enquêtes et questionnaires , Adulte , Humains , Adulte d'âge moyen , République de Corée , Jeune adulte
11.
Int J Nanomedicine ; 9 Suppl 2: 21-7, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565823

RÉSUMÉ

PURPOSE: This study examined the need for public communication about nanotechnologies and nanoparticles by providing a comparative analysis of the differences in risk awareness of nanotechnologies and nanoparticles between consumers and experts. METHODS: A total of 1,007 consumers and 150 experts participated in this study. A questionnaire was prepared examining their awareness of nanotechnologies and nanomaterials and their view of the necessity for information and education about the latest nanotechnologies and nanomaterials. RESULTS: Our results indicated that the expert group recognized that they knew more than consumers about nanotechnology and that there was a need for relevant education in nanotechnology and nanomaterials among consumers. We found that the consumer group had a more positive attitude toward nanotechnology, even though they did not know much about it. Moreover, the consumer group was inconclusive about the type of information on nanotechnology deemed necessary for the public, as well as the suitable party to be responsible for education and for delivering the information. CONCLUSION: An education and promotion program targeting consumers should be established to overcome the differences between consumers and experts in their awareness of nanotechnology. Specifically, the establishment of concepts for nanomaterials or nanoproducts is required immediately. With clear standards on nanomaterials, consumers can make informed decisions in selecting nanoproducts in the market.


Sujet(s)
Comportement du consommateur , Connaissances, attitudes et pratiques en santé , Nanostructures , Nanotechnologie , Humains , République de Corée
12.
Int J Nanomedicine ; 9 Suppl 2: 41-56, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565825

RÉSUMÉ

In this study, four types of standardized ZnO nanoparticles were prepared for assessment of their potential biological risk. Powder-phased ZnO nanoparticles with different particle sizes (20 nm and 100 nm) were coated with citrate or L-serine to induce a negative or positive surface charge, respectively. The four types of coated ZnO nanoparticles were subjected to physicochemical evaluation according to the guidelines published by the Organisation for Economic Cooperation and Development. All four samples had a well crystallized Wurtzite phase, with particle sizes of ∼30 nm and ∼70 nm after coating with organic molecules. The coating agents were determined to have attached to the ZnO surfaces through either electrostatic interaction or partial coordination bonding. Electrokinetic measurements showed that the surface charges of the ZnO nanoparticles were successfully modified to be negative (about -40 mV) or positive (about +25 mV). Although all the four types of ZnO nanoparticles showed some agglomeration when suspended in water according to dynamic light scattering analysis, they had clearly distinguishable particle size and surface charge parameters and well defined physicochemical properties.


Sujet(s)
Nanoparticules métalliques/composition chimique , Oxyde de zinc/composition chimique , Taille de particule , Électricité statique , Propriétés de surface
13.
Int J Nanomedicine ; 9 Suppl 2: 67-78, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565827

RÉSUMÉ

This study was undertaken to investigate the potential toxicity and establish the no observed adverse effect level (NOAEL) and target organ(s) of negatively charged colloidal silica particles of different sizes, ie, SiO2 (EN20(-)) (20 nm) or SiO2 (EN100(-)) 2(100 nm), administered by gavage in Sprague-Dawley rats. After verification of the physicochemical properties of the SiO2 particles to be tested, a preliminary dose range-finding study and 90-day repeated dose study were conducted according to the Organisation for Economic Cooperation and Development test guideline. Based on the results of the 14-day dose range-finding study, a high dose was determined to be 2,000 mg/kg, and middle and low doses were set at 1,000 and 500 mg/kg, respectively. In the 90-day toxicity study, there were no animal deaths in relation to administration of SiO2 particles of either size. In addition, no treatment-related clinical changes or histopathological findings were observed in any of the experimental groups. Moreover, no difference in toxic effects from chronic exposure to SiO2 (EN20(-))(20 nm) or SiO2 (EN100(-)) (100 nm) was observed. The results of this study indicate that the NOAEL for SiO2 (EN20(-)) and SiO2 (EN100(-)) would most likely be 2,000 mg/kg, and no target organ was identified in rats of either sex.


Sujet(s)
Colloïdes , Nanoparticules , Silice , Administration par voie orale , Animaux , Colloïdes/administration et posologie , Colloïdes/composition chimique , Colloïdes/toxicité , Nanoparticules/administration et posologie , Nanoparticules/composition chimique , Nanoparticules/toxicité , Dose sans effet nocif observé , Rats , Rat Sprague-Dawley , Silice/administration et posologie , Silice/composition chimique , Silice/toxicité , Tests de toxicité chronique
14.
Int J Nanomedicine ; 9 Suppl 2: 79-92, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565828

RÉSUMÉ

PURPOSE: The widespread use of nanoparticles (NPs) in industrial and biomedical applications has prompted growing concern regarding their potential toxicity and impact on human health. This study therefore investigated the subchronic, systemic oral toxicity and no-observed-adverse-effect level (NOAEL) of 20 nm, negatively charged zinc oxide (ZnO(SM20(-))) NPs in Sprague Dawley rats for 90 days. METHODS: The high-dose NP level was set at 500 mg/kg of bodyweight, and the mid- and low-dose levels were set at 250 and 125 mg/kg, respectively. The rats were observed during a 14-day recovery period after the last NP administration for the persistence or reduction of any adverse effects. Toxicokinetic and distribution studies were also conducted to determine the systemic distribution of the NPs. RESULTS: No rats died during the test period. However, ZnO(SM20(-)) NPs (500 mg/kg) induced changes in the levels of anemia-related factors, prompted acinar cell apoptosis and ductular hyperplasia, stimulated periductular lymphoid cell infiltration and excessive salivation, and increased the numbers of regenerative acinar cells in the pancreas. In addition, stomach lesions were seen at 125, 250, and 500 mg/kg, and retinal atrophy was observed at 250 and 500 mg/kg. The Zn concentration was dose-dependently increased in the liver, kidney, intestines, and plasma, but not in other organs investigated. CONCLUSION: A ZnO(SM20(-)) NP NOAEL could not be established from the current results, but the lowest-observed-adverse-effect level was 125 mg/kg. Furthermore, the NPs were associated with a number of undesirable systemic actions. Thus, their use in humans must be approached with caution.


Sujet(s)
Nanoparticules métalliques , Oxyde de zinc , Administration par voie orale , Animaux , Anions , Apoptose/effets des médicaments et des substances chimiques , Nanoparticules métalliques/administration et posologie , Nanoparticules métalliques/composition chimique , Nanoparticules métalliques/toxicité , Pancréas/effets des médicaments et des substances chimiques , Taille de particule , Rats , Rat Sprague-Dawley , Distribution tissulaire , Tests de toxicité subchronique , Oxyde de zinc/administration et posologie , Oxyde de zinc/composition chimique , Oxyde de zinc/pharmacocinétique , Oxyde de zinc/toxicité
15.
Int J Nanomedicine ; 9 Suppl 2: 93-107, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565829

RÉSUMÉ

PURPOSE: The study reported here was conducted to determine the systemic oral toxicity and to find the no-observed-adverse-effect level of 20 nm positively charged zinc oxide (ZnO(SM20(+))) nanoparticles in Sprague Dawley rats for 90 days. METHODS: For the 90-day toxicity study, the high dose was set as 500 mg per kg of body weight (mg/kg) and the middle and low dose were set to 250 mg/kg and 125 mg/kg, respectively. The rats were held for a 14-day recovery period after the last administration, to observe for the persistence or reduction of any toxic effects. A distributional study was also carried out for the systemic distribution of ZnO(SM20(+)) NPs. RESULTS: No rats died during the test period. There were no significant clinical changes due to the test article during the experimental period in functional assessment, body weight, food and water consumption, ophthalmological testing, urine analysis, necropsy findings, or organ weights, but salivation was observed immediately after administration in both sexes. The total red blood cell count was increased, and hematocrit, albumin, mean cell volume, mean cell hemoglobin, and mean cell hemoglobin concentration were decreased significantly compared with control in both 500 mg/kg groups. Total protein and albumin levels were decreased significantly in both sexes in the 250 and 500 mg/kg groups. Histopathological studies revealed acinar cell apoptosis in the pancreas, inflammation and edema in stomach mucosa, and retinal atrophy of the eye in the 500 mg/kg group. CONCLUSION: There were significant parameter changes in terms of anemia in the hematological and blood chemical analyses in the 250 and 500 mg/kg groups. The significant toxic change was observed to be below 125 mg/kg, so the no-observed-adverse-effect level was not determined, but the lowest-observed-adverse-effect level was considered to be 125 mg/kg in both sexes and the target organs were found to be the pancreas, eye, and stomach.


Sujet(s)
Nanoparticules métalliques , Oxyde de zinc , Administration par voie orale , Animaux , Apoptose/effets des médicaments et des substances chimiques , Cations , Oedème , Nanoparticules métalliques/administration et posologie , Nanoparticules métalliques/composition chimique , Nanoparticules métalliques/toxicité , Pancréas/effets des médicaments et des substances chimiques , Taille de particule , Rats , Rat Sprague-Dawley , Distribution tissulaire , Tests de toxicité subchronique , Oxyde de zinc/administration et posologie , Oxyde de zinc/composition chimique , Oxyde de zinc/pharmacocinétique , Oxyde de zinc/toxicité
16.
Int J Nanomedicine ; 9 Suppl 2: 109-26, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565830

RÉSUMÉ

Nanoparticles (NPs) are used commercially in health and fitness fields, but information about the toxicity and mechanisms underlying the toxic effects of NPs is still very limited. The aim of this study is to investigate the toxic effect(s) of 100 nm negatively (ZnO(AE100[-])) or positively (ZnO(AE100[+])) charged zinc oxide (ZnO) NPs administered by gavage in Sprague Dawley rats, to establish a no observed adverse effect level, and to identify target organ(s). After verification of the primary particle size, morphology, hydrodynamic size, and zeta potential of each test article, we performed a 90-day study according to Organisation for Economic Co-operation and Development test guideline 408. For the 90-day study, the high dose was set at 500 mg/kg and the middle and low doses were set at 125 mg/kg and 31.25 mg/kg, respectively. Both ZnO NPs had significant changes in hematological and blood biochemical analysis, which could correlate with anemia-related parameters, in the 500 mg/kg groups of both sexes. Histopathological examination showed significant adverse effects (by both test articles) in the stomach, pancreas, eye, and prostate gland tissues, but the particle charge did not affect the tendency or the degree of the lesions. We speculate that this inflammatory damage might result from continuous irritation caused by both test articles. Therefore, the target organs for both ZnO(AE100(-)) and ZnO(AE100(+)) are considered to be the stomach, pancreas, eye, and prostate gland. Also, the no observed adverse effect level for both test articles was identified as 31.25 mg/kg for both sexes, because the adverse effects were observed at all doses greater than 125 mg/kg.


Sujet(s)
Nanoparticules métalliques , Oxyde de zinc , Administration par voie orale , Animaux , Femelle , Mâle , Nanoparticules métalliques/administration et posologie , Nanoparticules métalliques/composition chimique , Nanoparticules métalliques/toxicité , Pancréas/effets des médicaments et des substances chimiques , Rat Sprague-Dawley , Estomac/effets des médicaments et des substances chimiques , Distribution tissulaire , Tests de toxicité , Oxyde de zinc/administration et posologie , Oxyde de zinc/composition chimique , Oxyde de zinc/pharmacocinétique , Oxyde de zinc/toxicité
17.
Int J Nanomedicine ; 9 Suppl 2: 127-36, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565831

RÉSUMÉ

Silica is a very common material that can be found in both crystalline and amorphous forms. Well-known toxicities of the lung can occur after exposure to the crystalline form of silica. However, the toxicities of the amorphous form of silica have not been thoroughly studied. The majority of in vivo studies of amorphous silica nanoparticles (NPs) were performed using an inhalation exposure method. Since silica NPs can be commonly administered through the skin, a study of dermal silica toxicity was necessary to determine any harmful effects from dermal exposures. The present study focused on the results of systemic toxicity after applying 20 nm colloidal silica NPs on rat skin for 90 days, in accordance with the Organization for Economic Cooperation and Development test guideline 411 with a good laboratory practice system. Unlike the inhalation route or gastrointestinal route, the contact of silica NPs through skin did not result in any toxicity or any change in internal organs up to a dose of 2,000 mg/kg in rats.


Sujet(s)
Exposition environnementale/analyse , Nanoparticules , Silice , Administration par voie cutanée , Animaux , Nanoparticules/administration et posologie , Nanoparticules/composition chimique , Nanoparticules/toxicité , Rats , Silice/administration et posologie , Silice/composition chimique , Silice/toxicité , Tests de toxicité chronique
18.
Int J Nanomedicine ; 9 Suppl 2: 137-44, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565832

RÉSUMÉ

Zinc oxide (ZnO) works as a long-lasting, broad-spectrum physical sunblock, and can prevent skin cancer, sunburn, and photoaging. Nanosized ZnO particles are used often in sunscreens due to consumer preference over larger sizes, which appear opaque when dermally applied. Although the US Food and Drug Administration approved the use of nanoparticles (NPs) in sunscreens in 1999, there are ongoing safety concerns. The aim of this study was to evaluate the subchronic toxicity of ZnO NPs after dermal application according to the Organization for Economic Cooperation and Development Test Guidelines 411 using Good Laboratory Practice. Sprague Dawley rats were randomly divided into eight (one control, one vehicle control, three experimental, and three recovery) groups. Different concentrations of ZnO NPs were dermally applied to the rats in the experimental groups for 90 days. Clinical observations as well as weight and food consumption were measured and recorded daily. Hematology and biochemistry parameters were determined. Gross pathologic and histopathologic examinations were performed on selected tissues from all animals. Analyses of tissue were undertaken to determine target organ tissue distribution. There was no increased mortality in the experimental group. Although there was dose-dependent irritation at the site of application, there were no abnormal findings related to ZnO NPs in other organs. Increased concentrations of ZnO in the liver, small intestine, large intestine, and feces were thought to result from oral ingestion of ZnO NPs via licking. Penetration of ZnO NPs through the skin seemed to be limited via the dermal route. This study demonstrates that there was no observed adverse effect of ZnO NPs up to 1,000 mg/kg body weight when they are applied dermally.


Sujet(s)
Nanoparticules , Oxyde de zinc , Administration par voie cutanée , Animaux , Nanoparticules/administration et posologie , Nanoparticules/composition chimique , Nanoparticules/toxicité , Rats , Rat Sprague-Dawley , Tests de toxicité chronique , Oxyde de zinc/administration et posologie , Oxyde de zinc/composition chimique , Oxyde de zinc/toxicité
19.
Int J Nanomedicine ; 9 Suppl 2: 145-57, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565833

RÉSUMÉ

This study investigated the potential adverse effects of zinc oxide nanoparticles (ZnO(SM20[-]) NPs; negatively charged, 20 nm) on pregnant dams and embryo-fetal development after maternal exposure over the period of gestational days 5-19 with Sprague Dawley rats. ZnO(SM20(-)) NPs were administered to pregnant rats by gavage at 0 mg/kg/day, 100 mg/kg/day, 200 mg/kg/day, and 400 mg/kg/day. All dams were subjected to caesarean section on gestational day 20, and all the fetuses were examined for external, visceral, and skeletal alterations. Toxicity in the dams manifested as significantly decreased body weight at 400 mg/kg/day and decreased liver weight, and increased adrenal glands weight at 200 mg/kg/day and 400 mg/kg/day. However, no treatment-related difference in the number of corpora lutea, the number of implantation sites, the implantation rate (%), resorption, dead fetuses, litter size, fetal deaths, fetal and placental weights, and sex ratio were observed between the groups. Morphological examinations of the fetuses demonstrated no significant difference in the incidences of abnormalities between the groups. No significant difference was found in the Zn content of fetal tissue between the control and high-dose groups. These results showed that a 15-day repeated oral dose of ZnO(SM20(-)) was minimally maternotoxic at dose of 200 mg/kg/day and 400 mg/kg/day.


Sujet(s)
Développement foetal/effets des médicaments et des substances chimiques , Nanoparticules métalliques , Oxyde de zinc , Animaux , Femelle , Nanoparticules métalliques/administration et posologie , Nanoparticules métalliques/composition chimique , Nanoparticules métalliques/toxicité , Grossesse , Rats , Rat Sprague-Dawley , Tests de toxicité , Oxyde de zinc/administration et posologie , Oxyde de zinc/composition chimique , Oxyde de zinc/toxicité
20.
Int J Nanomedicine ; 9 Suppl 2: 159-71, 2014.
Article de Anglais | MEDLINE | ID: mdl-25565834

RÉSUMÉ

This study investigated the potential adverse effects of zinc oxide nanoparticles ([ZnO(SM20(+)) NPs] zinc oxide nanoparticles, positively charged, 20 nm) on pregnant dams and embryo-fetal development after maternal exposure over the period of gestational days 5-19 with Sprague-Dawley rats. ZnO(SM20(+)) NPs were administered to pregnant rats by gavage at 0, 100, 200, and 400 mg/kg/day. All dams were subjected to a cesarean section on gestational day 20, and all of the fetuses were examined for external, visceral, and skeletal alterations. Toxicity in the dams manifested as significantly decreased body weight after administration of 400 mg/kg/day NPs; reduced food consumption after administration of 200 and 400 mg/kg/day NPs; and decreased liver weight and increased adrenal glands weight after administration of 400 mg/kg/day NPs. However, no treatment-related difference in: number of corpora lutea; number of implantation sites; implantation rate (%); resorption; dead fetuses; litter size; fetal deaths and placental weights; and sex ratio were observed between the groups. On the other hand, significant decreases between treatment groups and controls were seen for fetal weights after administration of 400 mg/kg/day NPs. Morphological examinations of the fetuses demonstrated significant differences in incidences of abnormalities in the group administered 400mg/kg/day. Meanwhile, no significant difference was found in the Zn content of fetal tissue between the control and high-dose groups. These results showed that oral doses for the study with 15-days repeated of ZnO(SM20(+)) NPs were maternotoxic in the 200 mg/kg/day group, and embryotoxic in the 400 mg/kg/day group.


Sujet(s)
Développement embryonnaire/effets des médicaments et des substances chimiques , Nanoparticules métalliques , Oxyde de zinc , Animaux , Femelle , Foie/effets des médicaments et des substances chimiques , Nanoparticules métalliques/administration et posologie , Nanoparticules métalliques/composition chimique , Nanoparticules métalliques/toxicité , Grossesse , Rats , Rat Sprague-Dawley , Tests de toxicité , Oxyde de zinc/administration et posologie , Oxyde de zinc/composition chimique , Oxyde de zinc/toxicité
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE